Senior IPS officer PSR Anjaneyulu hospitalised in Vijayawada GGH amid APPSC Group-1 scam investigation
VIJAYAWADA: Senior IPS officer and former Intelligence chief PSR Anjaneyulu, currently in judicial remand in connection with the alleged APPSC Group-1 examination evaluation scam, was admitted to Vijayawada GGH on Saturday afternoon.
This marks the second time Anjaneyulu has been hospitalised since his remand, after developing health complications in jail.
According to jail authorities, Anjaneyulu was rushed to the hospital around 10 am after experiencing sudden blood pressure fluctuations and giddiness. Doctors provided initial treatment and later moved him to the general ward for observation. His condition was monitored through the evening, and a detailed medical report was submitted to police and jail authorities.
Anjaneyulu recently secured bail in a harassment case involving a doctor and Mumbai-based actress Kadambari Jethwani. He is still awaiting bail in the APPSC scam case.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
28 minutes ago
- Time of India
Insta row: Kol, Assam cops slap FIR on man who filed plaint; cases also in Delhi
1 2 3 Kolkata/Guwahati: Wazahat Khan Qadri, the man whose FIR led to the arrest of a 22-year-old Instagram influencer and fourth-year law student of a Pune-based university for allegedly hurting religious sentiments in an Instagram video, is "untraceable" since Sunday, a police officer said. Multiple FIRs have been lodged against Qadri in Kolkata, Assam, and Delhi. In Kolkata, an FIR has been lodged at Golf Green PS. KP cyber cell is probing another plaint filed in Garden Reach PS for denigrating Hindu deities. A case has been registered in Assam against Qadri for allegedly denigrating several Hindu deities, including Goddess Kamakhya. Assam Police have not made any official statement regarding the case till now. It was registered at Panbazar police station in Guwahati. Based on his abusive posts, two criminal complaints were also lodged in New Delhi for communal provocation aimed at disturbing social harmony. The Shree Ram Swabhiman Parishad also filed a complaint, accusing Khan of mocking Hindu traditions, festivals, and temples to incite communal tensions. Qadri's father, Saadaq Khan, claimed that there was a "witch hunt" for his arrest ever since the Instagrammer's arrest and denied that he hated any religion, suggesting that Qadri's accounts were probably "hacked". by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Is your accounts payable process optimized? expertinspector Undo "My son is innocent and secular. He cannot insult Hinduism. We have been receiving threats since Sharmistha's arrest," he said. "It has come to light that Khan started deleting several of his controversial social media posts as the student's arrest led to increased scrutiny on his accounts," said a police source. The student was arrested late on May 30 in Gurugram by KP and placed in 14-day judicial custody over a controversial video in which she criticised Muslim Bollywood celebrities for staying silent on 'Operation Sindoor'. According to her lawyer Md Samimuddin, his client is suffering from kidney stones and lacks access to basic amenities, including reading materials and proper hygiene facilities. A petition has been filed seeking to secure her fundamental rights while in custody.
Mint
30 minutes ago
- Mint
Zydus buys Agenus' biologics plants in US for $125 mn, licenses cancer therapy
Zydus Lifesciences announced on Tuesday it is acquiring two biologics contract manufacturing facilities in California from US-based Agenus Inc for a total consideration of up to $125 million. The deal includes an upfront payment of $75 million, with the remaining $50 million to be paid over the following three years. The Ahmedabad-based pharmaceutical firm said the acquisition will establish its presence in the rapidly-expanding global biologics contract development and manufacturing organization (CDMO) sector. Zydus is also acquiring a 5.9% stake in Agenus for $16 million, through its wholly-owned subsidiary Zynext Ventures USA LLC, it said in an exchange filing on Tuesday. The drugmaker has also entered into a licensing agreement with Agenus to commercialise its investigational Botensilimab (BOT) and Balstilimab (BAL) combination therapy in India and Sri Lanka. Agenus is a clinical-stage immuno-oncology company committed to developing immune therapies against cancer. The move to acquire biologics manufacturing facilities in the US aligns with Zydus' strategic focus on biologics as a key growth driver this year. Also Read: Glenmark-Ichnos cancer drug shows 74% response in phase-1 trial "The acquisition will give Zydus a strategic foothold in the US for biologics manufacturing in the global hub for biotech innovation, California," managing director Sharvil Patel said in a statement. 'This move strengthens our long-term biologics vision and positions us to better serve the evolving needs of the global biopharmaceutical industry," he added. Additionally, the acquisition gives the company a stronger manufacturing presence in the US, amid ongoing uncertainties over potential American tariffs on pharmaceutical imports. In the company's earnings call last month, Patel had said the company is evaluating opportunities for local manufacturing in the US. 'We have committed to making a good amount of investments in the US with our foray into specialty and other areas," he told investors. Exclusive manufacturer to Agenus Under the terms of the agreement, Zydus will acquire two modern biologics manufacturing facilities from Agenus in Emeryville and Berkeley, California, for an upfront consideration of $75 million and contingent payment of $50 million to be paid over three years subject to achievement of certain revenue milestone. The acquisition provides Zydus immediate access to advanced biologics manufacturing capabilities and a foothold in California, a leading global biotech hub. The move also enables Zydus to 'leverage supply chain dynamics and a favourable geopolitical environment to expand its reach in the U.S. and globally," it said in the release. Also Read: KKR provides $600 mn financing to Manipal Group to fuel its corporate expansion The CDMO business will operate as an independent entity and will house the acquired manufacturing capabilities. As part of the transaction, Zydus will become the exclusive contract manufacturer for Agenus, and provide manufacturing services for the clinical and commercial supply of two identified Phase-3 ready immuno-oncology products - Botensilimab and Balstilimab. Zydus will also have the first right of negotiation to manufacture any of the future pipeline products by Agenus. Agenus reported a turnover of $103.46 million in 2024, according to the exchange filing. Agenus' lead programme comprising Botensilimab and Balstilimab is a next-generation immunotherapy platform designed to strengthen and sustain the immune system's response against tumour cells. The platform, which is currently in advanced clinical trials, has demonstrated significant clinical activity across nine cancer types in more than 1,200 patients, including both late-stage and patients who have undergone neoadjuvant, or primary, therapy. As part of the licensing agreement inked with Agenus, Zydus will be responsible for clinical development and regulatory approvals of the licensed products in India and Sri Lanka and will pay 5% royalty on net sales upon successful approval and commercialization. Also Read: Young heirs take charge as Indian pharma firms plan succession Zydus will expand the reach of the therapy within its initial indications, as well as drive its expansion into other high unmet need indications and earlier lines of treatment, including primary treatments, the company said.
&w=3840&q=100)
Business Standard
41 minutes ago
- Business Standard
Sansera Engineering wins ₹160 crore Airbus deal for airborne ICT modules
Sansera Engineering Limited has signed a major long-term agreement with Airbus Defence and Space, valued at ₹160 crore (approximately $18.8 million). The Bengaluru-based precision engineering company will manufacture, supply and support airborne Intensive Care Transport Modules (ICTM) for Airbus' light and medium transport aircraft programmes. First Airbus ICTM contract awarded to an Indian supplier The ICTM is a vital medical evacuation system designed for transporting patients, including those in intensive care, during emergencies and health crises. It is a key component in defence and humanitarian missions. This is the first time Airbus has selected an Indian company to supply the ICTM kit, marking a significant milestone in both Sansera's global expansion and India's growing capabilities in aerospace manufacturing. The agreement covers complete manufacturing, delivery and ongoing support for the ICTM units. Sansera will carry out precision machining and structural assembly. It also marks the first formal partnership between Airbus and Sansera for such a specialised aerospace project in India. S Sekhar Vasan, Chairman and Managing Director of Sansera Engineering, said, 'I am proud to announce that Sansera has been selected as the Indian supply chain partner for Airbus, a leading global aerospace and defence company. This strategic partnership positions us as their trusted supplier for the Airborne Intensive Care Transport Module for light and medium transport aircraft programmes, marking a significant milestone in our journey as a precision manufacturing leader.' 'This achievement reflects decades of excellence in innovation, automation and quality that have established Sansera as a trusted name in the global aerospace supply chain and defence industry. It also strengthens the Hon'ble Prime Minister's Make in India initiative by establishing advanced aerospace manufacturing capabilities in India and supports the country's journey towards self-reliance in critical defence and aerospace technologies,' he added. In addition to aerospace and defence, Sansera Engineering is a key player in the automotive sector. The company manufactures essential components for engines, transmissions, braking systems, suspension and chassis across two-wheelers, passenger vehicles and commercial vehicles. Sansera also supplies critical parts to the semiconductor manufacturing industry, further diversifying its presence across high-tech and precision-driven sectors.
